Comment on

• Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction.

  Yao X, Shah ND, Sangaralingham LR, Gersh BJ, Noseworthy PA. Yao X, et al. J Am Coll Cardiol. 2017 Jun 13;69(23):2779-2790. doi: 10.1016/j.jacc.2017.03.600. J Am Coll Cardiol. 2017. PMID: 28595692
• Authors Have Incorrectly Calculated Need for Renal Dose Adjustments for NOACs.

  Schwartz JB. Schwartz JB. J Am Coll Cardiol. 2017 Nov 28;70(21):2731-2732. doi: 10.1016/j.jacc.2017.08.077. J Am Coll Cardiol. 2017. PMID: 29169485 No abstract available.
• Renal Risk Stratification Tool to Guide NOAC Dosing in Patients With Renal Dysfunction.

  Pazmiño PA. Pazmiño PA. J Am Coll Cardiol. 2017 Nov 28;70(21):2732-2733. doi: 10.1016/j.jacc.2017.09.1093. J Am Coll Cardiol. 2017. PMID: 29169486 No abstract available.
• NOAC Dosing in Atrial Fibrillation and Renal Dysfunction: What Measure Are You Using?

  Shroff GR. Shroff GR. J Am Coll Cardiol. 2017 Nov 28;70(21):2733-2734. doi: 10.1016/j.jacc.2017.09.1091. J Am Coll Cardiol. 2017. PMID: 29169487 No abstract available.